| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | PHARNEXT: Pharnext takes full stock of its operating, strategic and financial situation | 379 | Actusnews Wire | PARIS, France, March 11, 2024, 04:30 pm CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative... ► Artikel lesen | |
| 28.02. | PHARNEXT: Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A | 418 | Actusnews Wire | PARIS, France, February 28, 2024, 08:30 am CET - Pharnext SA ( FR001400N1P4 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 17.01. | PHARNEXT: Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A | 448 | Actusnews Wire | PARIS, France, January 17, 2024, 08:30 am CET - Pharnext SA (FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative... ► Artikel lesen | |
| 19.12.23 | PHARNEXT: Pharnext intends to prepare registration and marketing authorization dossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A | 345 | Actusnews Wire | PARIS, France, December 19, 2023, 08:30 am CET - Pharnext SA (FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 13.12.23 | Pharnext hit again as rare disease drug flunks phase 3 test | 16 | pharmaphorum | ||
| 11.12.23 | Pharnext blames 'unexpected' placebo results for lead neurological drug's phase 3 failure | 10 | FierceBiotech | ||
| 11.12.23 | PHARNEXT: Pharnext reports topline results from the pivotal Phase III clinical trial (PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A | 523 | Actusnews Wire | PARIS, France, December 11, 2023, 08:30 am CET - Pharnext SA (FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 04.12.23 | PHARNEXT: Pharnext announces database lock for PXT3003 pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A, last step before topline results publication | 446 | Actusnews Wire | PARIS, France, December 4, 2023, 08:30 am CET - Pharnext SA ( FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 27.11.23 | PHARNEXT: Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A | 410 | Actusnews Wire | PARIS, France, November 27, 2023, 08:30 am CET - Pharnext SA ( FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 23.11.23 | Pharnext set to release pivotal trial data for CMT1A treatment PXT3003 | 9 | Investing.com | ||
| 23.11.23 | PHARNEXT: Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A | 539 | Actusnews Wire | PARIS, France, November 23, 2023, 08:30 am CET - Pharnext SA ( FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen | |
| 20.11.23 | PHARNEXT: Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States | 454 | Actusnews Wire | PARIS, France, November 20, 2023, 08:30 am CET - Pharnext SCA ( FR001400JXB0 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.485 |
| NEL | 2.172 |
| SIEMENS ENERGY | 1.937 |
| MERCEDES-BENZ | 1.918 |
| TUI | 1.562 |
| BAYER | 1.559 |
| PALANTIR TECHNOLOGIES | 1.397 |
| ALLIANZ | 1.359 |
| NVIDIA | 1.108 |
| DEUTSCHE BANK | 1.107 |
| BYD | 1.097 |
| PLUG POWER | 1.068 |
| DEUTSCHE LUFTHANSA | 1.061 |
| INFINEON | 903 |
| PUMA | 880 |
| VARTA | 869 |
| BORUSSIA DORTMUND | 846 |
| RWE | 818 |
| VOLKSWAGEN | 815 |
| SMA SOLAR | 790 |
| TESLA | 762 |
| RHEINMETALL | 758 |
| AIXTRON SE | 745 |
| RENK GROUP | 737 |
| SUPER MICRO COMPUTER | 724 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
